Navigation Links
Jubilant and Endo Pharmaceuticals Announce Successful Delivery of Early Milestones in Collaborative Discovery Program
Date:2/9/2012

BANGALORE, India, February 9, 2012 /PRNewswire/ --

Jubilant Biosys Ltd., a Bengaluru-based subsidiary of Jubilant Life Sciences Ltd., announced today that they have achieved an early stage milestone in one of their collaborative programs with Chadds Ford, Pa., USA-based Endo Pharmaceuticals that has nominated a candidate into full development. The novel molecule, targeting cancer, is anticipated to go into clinical trials by late 2012. Jubilant and Endo will continue the collaboration in the development phase as well.  

The multi-target collaboration that began three years ago focuses on Best in Class differentiated therapies to address the unmet needs of cancer patients worldwide.  The collaboration has since delivered multiple milestones across the discovery phase.  Endo will pursue development and commercialization of the compound, while Jubilant becomes eligible to receive development milestones.

"We are very pleased and elated with this successful outcome, which is a result of the excellent collaboration between the scientists at Endo and Jubilant," said Sri Mosur, CEO & President, Global Drug Discovery and Development, Jubilant. "Jubilant has pioneered from India, a business model based on shared risk that enables it to demonstrate the differentiated and novel outcomes that Jubilant scientists are able to deliver through accelerated and affordable innovation to its many collaborators."

Sandeep Gupta, Endo Pharmaceuticals, Senior Vice President, Discovery & Early Development , said, "I congratulate the Jubilant and Endo teams on achieving this important milestone. It was their outstanding collaborative work and ingenuity that enabled nomination of a development candidate ahead of schedule in less than two years since inception of this program. Initiation of this development program further validates Endo's unique collabrative drug discovery approach which aims to address unmet medical needs and improve patient outcomes."  

About Us

Jubilant Biosys Ltd. is a Bengaluru based subsidiary of Jubilant Life Sciences Ltd, headquartered in Noida, India. Jubilant Biosys, provides integrated drug discovery and development solutions to the global pharmaceutical industry. It is a pioneer in collaborative discovery research and development and is engaged in multiple partnerships with global pharmaceutical industry in therapeutic areas of Oncology, CNS and CVMED.

http://www.jubilantbiosys.com

Contact For Business Queries

Narendra Kumar
+91(0)80-6662840
narendra_kumar@jubilantbiosys.com


'/>"/>
SOURCE Jubilant Biosys Ltd and Endo Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Jubilant HollisterStier Allergy Launches Allergy Industry Insights Educational Webinar Series
2. Jubilant and AstraZeneca Announce Successful Delivery of Early Milestones in Drug Discovery
3. Jubilant Organosys, UAB and Southern Research Enter Into Drug Discovery Joint Venture
4. Jubilant Enters Research Collaboration With AstraZeneca
5. Syndax Pharmaceuticals Announces Entinostat Enhanced Activity of Cancer Immunotherapies in Renal and Prostate Cancer Models
6. Avanir Pharmaceuticals Announces Publication of Phase III Study Results Showing Efficacy and Safety of AVP-923 in the Treatment of Diabetic Neuropathic Pain
7. Prismic Pharmaceuticals Acquires Scaristas Exclusive License to Amarins Omega-3 Patents for CNS Disorders
8. Amylin Pharmaceuticals Reports Fourth Quarter and Full Year 2011 Financial Results
9. Cadence Pharmaceuticals Announces Voluntary Recall of One Lot of OFIRMEV® (Acetaminophen) Injection
10. Valeant Pharmaceuticals Completes Divestiture of Generic Dermatology Products to Mylan
11. Generic Pharmaceuticals Market - A Global Analysis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... CITY , Dec. 8, 2016 ... US patents for improving the accuracy, reproducibility and ... images in long and small bone orthopaedic applications. ... approach to creating personalized orthopaedic restorations based on ... personalized orthopaedic restorations, the company harnesses the world,s ...
(Date:12/8/2016)... 2016  A new study by a pair of ... opioid therapy to treat chronic pain is not only ... harmful consequences, including death. Palliative care physicians ... Mehta , M.D., authored the study which provides a ... The study was published in the December 2016 edition ...
(Date:12/8/2016)... December 8, 2016 Information products and services ... in Scopus , the world,s largest abstract and citation ... comprehensive metrics for journals from over 5,000 publishers. The new set ... to subscribe to and when to adjust a journal,s editorial strategy. ... , , ...
Breaking Medicine Technology:
(Date:12/9/2016)... ... December 09, 2016 , ... The Justin Veatch ... Inc. (NCADD) is recommending the film Whispering Spirits and its discussion ... of Columbia as an education tool in the war against teen drug abuse. ...
(Date:12/9/2016)... ... December 09, 2016 , ... MEDI+SIGN®, a ... today that a new solution for Emergency Departments (ED) has been added to ... in Emergency Department examination rooms, and with a simplified pallet of information available ...
(Date:12/8/2016)... ... December 08, 2016 , ... After ... officially opened registration today for its 33rd Annual Issues & Research Conference, ... , The theme of the conference is “Persistent Challenges and New Opportunities: Using ...
(Date:12/8/2016)... ... December 08, 2016 , ... CURE Media Group, the ... advocacy groups, has aligned with Upstage Lung Cancer in efforts to combat lung cancer, ... Michael J. Hennessy, Jr said, “CURE Media Group is honored to team up with ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... 10.2 version gives development continuity to its innovative Unified Instance Manager architecture, ... capacity. In addition, this new version optimizes the unattended auto-dialing system without ...
Breaking Medicine News(10 mins):